Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" Trial

NCT05118490 is registered in ClinicalTrials.gov with The Aurum Institute NPC as lead sponsor.

NCT NCT05118490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05118490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" Trial
Lead sponsor
The Aurum Institute NPC
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 19, 2023
Completion date
December 31, 2025
Enrollment
1,000 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv seropositivity, household contact, tuberculosis